Summary
GNPX Chart
Genprex, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| ABB Alexander Bjornager Bonde Danske Bank A/S | 0.04 | $1.75 | $0.5 | -$1.25 | -71.43% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 5.4 | $217.2 | $58.87 | -$158.33 | -72.9% |
| HFT Hui Fai Tam Caitong International Asset Management Co. Ltd. | 2 | $3.62 | $16.55 | $12.93 | 357.18% |
 Nemes Rush Group LLC Nemes Rush Group LLC | 5 | $9 | $40.05 | $31.05 | 345% |
 Lyn Dippel Curio Wealth LLC | - | $1.75 | $0.01 | -$1.74 | -99.43% |
Genprex, Inc. (GNPX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Genprex, Inc. ever had a stock split?
Genprex, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Ryan Confer CEO | NASDAQ (CM) Exchange | 372446302 CUSIP |
| US Country | 13 Employees | - Last Dividend | 16 Jul 2026 Last Split | 29 Mar 2018 IPO Date |
Overview
Genprex, Inc. is a clinical-stage gene therapy company dedicated to developing innovative treatments for patients with cancer and diabetes. With its focus on groundbreaking gene therapy techniques, Genprex is at the forefront of medical research in its mission to address some of the most challenging diseases facing patients today. The company was established in 2009 and has since been headquartered in Austin, Texas, where it continues to push the boundaries of medical science with its advanced clinical trials and research initiatives.
Products and Services
REQORSA (GPX-001): This lead product candidate of Genprex, Inc. is currently undergoing Phase 1/2 and 2 clinical trials. Developed as a treatment option for non-small cell lung cancer and small cell lung cancer, REQORSA represents a significant advancement in the field of oncology gene therapy. It showcases the company's dedication to combating cancer through innovative genetic approaches.
GPX-002: Focused on the treatment of type 1 diabetes, GPX-002 is another pioneering project by Genprex. It reflects the company's commitment to expanding its research and development efforts beyond oncology, addressing other critical areas of medical need. By exploring the potential of gene therapy in treating type 1 diabetes, Genprex is working towards providing new hope and solutions for patients affected by this challenging condition.
GPX-003: This product candidate is being developed for the treatment of type 2 diabetes. Similar to GPX-002, GPX-003 underscores Genprex's pursuit of innovative gene therapy solutions for diabetes patients. With type 2 diabetes affecting a significant portion of the global population, the development of GPX-003 signifies an important step forward in the quest to provide more effective and groundbreaking treatments for diabetes.
